Stanford



Mr Mark Blumling

Lecturer, Law Teaching

Bio

BIO

A passionate advocate of healthcare and life sciences innovation, Mark has devoted his 25+ year career to improving patient health. Mark is currently an Advisor at Goldman Sachs Growth Equity, an Executive in Residence at Patient Square Capital, and Adjunct Faculty/Lecturer at Stanford Law School.

Mark is the former CEO and Founder of Headlands Research, a KKR-backed clinical research site company (acquired in 2025). He was previously CEO and Co-Founder of Genos, a big data healthcare technology company (acquired in 2017) and CEO of Relevare Pharmaceuticals, a pharmaceutical company based in San Francisco and Australia. Prior to joining Relevare, Mark was Founder and COO of Hyperion Therapeutics (NASDAQ: HPTX; acquired May 2015).

Mark received a JD from Stanford Law School, an MSc (Economics) from the London School of Economics, and a BA in Human Biology from Stanford University. He is a Member of the Council on Foreign Relations.

ACADEMIC APPOINTMENTS

- Lecturer, Law Teaching

Teaching

COURSES

2026-27

- Creating Value: Private Equity, Venture Capital and Entrepreneurism: LAW 1084 (Aut)

2025-26

- Creating Value: Private Equity, Venture Capital and Entrepreneurism: LAW 1084 (Aut)

2024-25

- S-Term: Creating Value: Private Equity, Venture Capital and Entrepreneurism: LAW 1084 (Aut)